By SPEAKIN’ OUT NEWS
A transformative $44 million federal biotechnology grant intended to elevate Birmingham as a national biotech leader has been revoked, dealing a major setback to the region’s research and economic development ambitions.
The Birmingham Biotechnology Hub, led by Southern Research, was slated to receive the funding to harness artificial intelligence in drug development, lower the cost of life-saving medications, and improve representation in clinical trials and genomic research. The project, which had broad bipartisan backing, has now been forc›ed to reapply under new Trump administration guidelines.
The grant was originally announced in January—just five days before President Donald Trump was sworn in for his second term.
A Collaborative Vision Halted
The grant followed a 2023 designation by the U.S. Department of Commerce that named Birmingham as one of 31 official Tech Hubs nationwide, qualifying it for substantial federal investment. Southern Research led the application alongside the University of Alabama at Birmingham (UAB), the City of Birmingham, and over 20 partner organizations spanning education, healthcare, and economic development.
In a joint statement, Southern Research and UAB acknowledged the setback but reaffirmed their commitment to the initiative:
“Southern Research and UAB are aware of our opportunity to compete for funding to support The Birmingham Biotechnology Hub alongside Hub partners and look forward to learning more about and participating in the process.”
Political Leaders Decry the Decision
U.S. Rep. Terri Sewell (D-AL) criticized the revocation, calling the decision “preposterous.”
“This investment was the result of years of planning and advocacy,” Sewell said. “It’s not fair. It’s not right.”
She suggested the project was targeted because it emphasized equitable clinical trials and genomic data diversity—goals that may no longer align with the Trump administration’s new funding criteria.
Sewell also noted the broad, bipartisan support behind the initiative:
“It had the strong backing of both Democrats and Republicans in Alabama because of its potential to create numerous jobs, improve health outcomes, and solidify the City of Birmingham as a biotechnology leader.”
In 2024, Sewell, along with U.S. Senator Katie Britt, Governor Kay Ivey, and Birmingham Mayor Randall Woodfin, co-authored an op-ed in Fortune Magazine, promoting Birmingham as the next great hub for American biotechnology.
“By nurturing biotech startups and supporting their growth, we will stimulate job creation, ensure regional economic competitiveness, and anchor the national bioeconomy,” the piece read.
Senator Britt Reaffirms Support
Sen. Katie Britt (R-AL) issued a statement reaffirming her backing of the Birmingham Biotech Hub, framing the initiative as crucial not just for Alabama, but for national security.
“Institutions like UAB and Tuskegee University, together with partners like Southern Research, form a dynamic and collaborative innovation ecosystem,” she said.
“This initiative is more than just an investment in Alabama—it is a strategic investment in our national security.”
Britt emphasized that advancing biotechnology domestically would help reduce the nation’s reliance on foreign adversaries for critical medical treatments.
“Birmingham is uniquely positioned to advance President Trump’s goal of global biomedical leadership, while onshoring our domestic supply chain of life-saving diagnostics and therapeutics.”
Next Steps Unclear
With the funding rescinded, Southern Research and its partners must now compete again under revised federal criteria. Attempts to reach the City of Birmingham for comment were unsuccessful at the time of publication.
Still, supporters of the initiative remain hopeful that the momentum behind the Birmingham Biotechnology Hub—and its promise of economic and health advancements—can be revived in the next round of competitive funding.